Drug Profile

QR 052

Alternative Names: QR-052; QR-052107B

Latest Information Update: 25 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Wuhan Createrna Science and Technology
Class Analgesics; Antitussives; Small molecules
Mechanism of Action Purinergic P2X3 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Cough; Pain

Most Recent Events

25 Dec 2023 Wuhan Createrna Science and Technology initiates enrolment in a phase II trial for Cough in China (PO) (NCT06920836)
21 Jun 2023 Wuhan Createrna Science and Technology initiates enrolment in a phase II trial for Cough in China (PO) (NCT06920836)
07 Dec 2022 Positive top-line adverse events and pharmacokinetics data from a phase I trial in Cough released by Createrna Science and Technology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com